JP4718172B2 - ヒトａｄａｍ−１０インヒビター - Google Patents

ヒトａｄａｍ−１０インヒビター Download PDF

Info

Publication number
JP4718172B2
JP4718172B2 JP2004513217A JP2004513217A JP4718172B2 JP 4718172 B2 JP4718172 B2 JP 4718172B2 JP 2004513217 A JP2004513217 A JP 2004513217A JP 2004513217 A JP2004513217 A JP 2004513217A JP 4718172 B2 JP4718172 B2 JP 4718172B2
Authority
JP
Japan
Prior art keywords
compound
mono
poly
substituted
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004513217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533789A5 (enExample
JP2005533789A (ja
Inventor
リン， カーン バネン，
エリック， ダブリュー． コー，
ヴァス ジャマラマダカ，
ジョン， エム． ナス，
ムーン， ホワン キム，
ドナ， トラ リー，
エイミー リュー ツハコ，
モリソン， ビー． マック，
シュメイ マモ，
ジャオヤン ウェン，
ウェイ シュー，
リチャード ジョージ ホウリ，
Original Assignee
シンフォニー エボルーション， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29736461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4718172(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シンフォニー エボルーション， インク． filed Critical シンフォニー エボルーション， インク．
Publication of JP2005533789A publication Critical patent/JP2005533789A/ja
Publication of JP2005533789A5 publication Critical patent/JP2005533789A5/ja
Application granted granted Critical
Publication of JP4718172B2 publication Critical patent/JP4718172B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/78—Halides of sulfonic acids
    • C07C309/86—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/87—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2004513217A 2002-06-12 2003-06-11 ヒトａｄａｍ−１０インヒビター Expired - Fee Related JP4718172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38832602P 2002-06-12 2002-06-12
US60/388,326 2002-06-12
PCT/US2003/018262 WO2003106381A2 (en) 2002-06-12 2003-06-11 Human adam-10 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010142096A Division JP2010265276A (ja) 2002-06-12 2010-06-22 ヒトａｄａｍ−１０インヒビター

Publications (3)

Publication Number Publication Date
JP2005533789A JP2005533789A (ja) 2005-11-10
JP2005533789A5 JP2005533789A5 (enExample) 2011-02-24
JP4718172B2 true JP4718172B2 (ja) 2011-07-06

Family

ID=29736461

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004513217A Expired - Fee Related JP4718172B2 (ja) 2002-06-12 2003-06-11 ヒトａｄａｍ−１０インヒビター
JP2010142096A Pending JP2010265276A (ja) 2002-06-12 2010-06-22 ヒトａｄａｍ−１０インヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010142096A Pending JP2010265276A (ja) 2002-06-12 2010-06-22 ヒトａｄａｍ−１０インヒビター

Country Status (7)

Country Link
US (5) US7629341B2 (enExample)
EP (3) EP2428509A1 (enExample)
JP (2) JP4718172B2 (enExample)
AU (2) AU2003237532B2 (enExample)
CA (1) CA2485346C (enExample)
ES (1) ES2425013T3 (enExample)
WO (1) WO2003106381A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US7494999B2 (en) * 2004-10-29 2009-02-24 Kalypsys, Inc Sulfonyl-substituted bicyclic compounds as modulators of PPAR
EP2428509A1 (en) 2002-06-12 2012-03-14 Symphony Evolution, Inc. Human adam-10 inhibitors
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
EP1623995A1 (en) * 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
US20090297507A1 (en) * 2005-04-07 2009-12-03 Albert Lai ADAM10 in Cancer Diagnosis, Detection and Treatment
WO2007051095A1 (en) * 2005-10-25 2007-05-03 Kalypsys, Inc. Salts of modulators of ppar and methods of treating metabolic disorders
EP1984500A2 (en) 2006-01-13 2008-10-29 Vanderbilt University Adam10 and its uses related to infection
CN100506804C (zh) * 2006-01-26 2009-07-01 于学敏 羟苯磺酸烷基吡嗪药物及其制备方法和应用
US20070249519A1 (en) * 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
TW200745059A (en) * 2006-05-16 2007-12-16 Kalypsys Inc Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US20080176861A1 (en) * 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
US8426415B2 (en) 2007-10-16 2013-04-23 Symphony Evolution, Inc. Human ADAM-10 inhibitors
CA3041868C (en) * 2008-10-09 2023-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase
WO2011041545A1 (en) 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
JP5888667B2 (ja) * 2010-04-30 2016-03-22 国立大学法人名古屋大学 Ａｄａｍ作用阻害物質のスクリーニング方法、仮足の保持方法、仮足保持剤、仮足の制御物質のスクリーニング方法、及びａｄａｍ作用阻害剤
WO2012064865A1 (en) 2010-11-09 2012-05-18 The University Of Chicago Role of adam10 and its relevance to disease and therapeutics
WO2014028334A1 (en) * 2012-08-11 2014-02-20 Symphony Evolution, Inc. Selective mmp inhibitors
US20170038382A1 (en) * 2014-01-24 2017-02-09 Ntercept, Llc Methods and compositions for immune dis-inhibition
KR20230042391A (ko) 2014-10-03 2023-03-28 나노틱스 엘엘씨 가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법
CN114146056A (zh) 2015-07-29 2022-03-08 纳米提克斯有限责任公司 用于清除可溶性生物分子的模块化组合物及其相关方法
EP3565604A4 (en) 2017-01-04 2020-09-09 Nanotics, LLC ELIMINATING PARTICLE ASSEMBLY PROCESSES
CN108947850B (zh) * 2018-07-23 2021-05-18 蚌埠中实化学技术有限公司 一种3,4,5-三氟苯胺的制备方法
EP3969035A4 (en) * 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
WO2021097376A1 (en) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN113563235B (zh) * 2021-07-28 2023-04-11 上海毕得医药科技股份有限公司 一种3-(卤代苯氧基)苯磺酰氯衍生物的合成方法
US20250177333A1 (en) * 2022-03-08 2025-06-05 Nova Southeastern University Method for treating rheumatoid arthritis (ra) using an enzyme-and substrate selective exosite inhibitor of a disintegrin and metalloprotease 10 (adam10)

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1016245A (en) 1962-11-06 1966-01-05 Ici Ltd Manufacture of polysulphones
US4213775A (en) * 1977-07-28 1980-07-22 Ube Industries, Ltd. Diphenyl ether derivatives and herbicidal compositions containing the same
DE3107700A1 (de) * 1981-02-28 1982-09-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von aromatischen sulfohalogeniden
DE69112847T2 (de) 1990-03-01 1996-03-14 Upjohn Co Pansenbakterie zur verhütung von akuten milchsäureazidose.
DE4015834A1 (de) * 1990-05-17 1991-11-21 Bayer Ag Phenoxyphenylsulfonylverbindungen
US5215549A (en) 1991-05-08 1993-06-01 Mobil Oil Corporation Thioester derived hindered phenols and aryl-amines as antioxidant and antiwear additives
DE4327026A1 (de) 1993-08-12 1995-02-16 Bayer Ag Arylsulfonyloxyphosphonsäurederivate
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
JP3837761B2 (ja) * 1995-08-04 2006-10-25 住友精化株式会社 ハロベンゼンスルホニルクロリド類の製造方法
DE19537334A1 (de) 1995-10-09 1997-04-10 Hoechst Ag Antiadhäsive Piperidin- und Pyrrolidin-Carbonsäuren
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
PT874830E (pt) * 1995-12-08 2003-06-30 Agouron Pharma Inibidor de metaloproteinases composicao farmaceutica contendo este inibidor e a utilizacao farmaceutica e metodo util para a sua preparacao
CA2264045A1 (en) 1996-08-28 1998-03-05 Randall Stryker Matthews Heterocyclic metalloprotease inhibitors
JP2000517185A (ja) 1996-08-29 2000-12-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 新規なメタロプロテアーゼファミリーｋｕｚ
US6333324B1 (en) 1996-12-17 2001-12-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of MMP or TNF
ATE223909T1 (de) 1997-01-23 2002-09-15 Hoffmann La Roche Sulfamide-metalloprotease inhibitoren
KR20000070923A (ko) 1997-02-11 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐 하이드록삼산 유도체
KR20010005940A (ko) * 1997-04-01 2001-01-15 아구론 파마슈티컬스, 인크. 메탈로프로테이나제 억제제를 포함하는 약제학적 조성물 및 이의 약제학적 용도
US5922546A (en) 1997-08-25 1999-07-13 Smithkline Beecham Corporation Human disintegrin metalloprotease KUZ gene
JP4327915B2 (ja) * 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
GT199900044A (es) * 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
WO1999058531A1 (en) 1998-05-14 1999-11-18 Du Pont Pharmaceuticals Company Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
CA2340182A1 (en) 1998-08-12 2000-02-24 Pfizer Products Inc. Tace inhibitors
US6509337B1 (en) 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
JP2000247975A (ja) 1999-02-25 2000-09-12 Nissan Chem Ind Ltd ヘテロ環縮合ピリミジノン誘導体及びそれらを含む除草剤
US6387901B1 (en) 1999-07-06 2002-05-14 Pfizer Inc Alkyne containing metalloproteinase inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
AU2001233034A1 (en) 2000-01-27 2001-08-07 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
JP4635162B2 (ja) * 2000-04-27 2011-02-16 独立行政法人理化学研究所 芳香族ジアミンの製造方法及び芳香族ジアミン化合物
AU2002255613A1 (en) 2001-02-27 2002-09-12 Axys Pharmaceuticals, Inc. Piperazine derivatives as metalloprotease inhibitors
CA2357110A1 (en) 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
US7223751B2 (en) 2001-04-26 2007-05-29 Kolon Ind. Inc. Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same
US6399823B1 (en) * 2001-04-30 2002-06-04 General Electric Company Method for producing phosgene
CN1610661A (zh) 2001-11-01 2005-04-27 惠氏控股公司 用作基质金属蛋白酶和tace的抑制剂的丙二烯芳基磺酰胺异羟肟酸
CN1173960C (zh) 2001-12-06 2004-11-03 中国人民解放军军事医学科学院毒物药物研究所 取代六元氮杂环类化合物及其作为神经调节剂的用途
WO2003051825A1 (en) * 2001-12-14 2003-06-26 Exelixis, Inc. Human adam-10 inhibitors
CA2471814C (en) 2001-12-27 2011-03-15 Sumitomo Pharmaceuticals Co., Ltd. Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
US7488754B2 (en) 2002-04-05 2009-02-10 Wyeth Method for the treatment of polycystic kidney disease
EP2428509A1 (en) 2002-06-12 2012-03-14 Symphony Evolution, Inc. Human adam-10 inhibitors
JP2006501215A (ja) 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
AU2004212335A1 (en) 2003-02-14 2004-08-26 Merck Serono Sa Piperazine-2-carboxamide derivatives
CA2516328A1 (en) 2003-02-18 2004-09-02 Pfizer Inc. Inhibitors of hepatitis c virus, compositions and treatments using the same
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
KR20080052611A (ko) 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds

Also Published As

Publication number Publication date
AU2003237532B2 (en) 2009-07-30
WO2003106381A2 (en) 2003-12-24
JP2010265276A (ja) 2010-11-25
US20120071653A1 (en) 2012-03-22
EP2428509A1 (en) 2012-03-14
AU2003237532A1 (en) 2003-12-31
US7989661B2 (en) 2011-08-02
EP1511488B1 (en) 2013-05-22
US20130144056A1 (en) 2013-06-06
CA2485346C (en) 2013-05-28
EP1511488A2 (en) 2005-03-09
US7629341B2 (en) 2009-12-08
EP1511488A4 (en) 2008-11-19
WO2003106381A3 (en) 2004-04-15
US20060199820A1 (en) 2006-09-07
EP2436676A1 (en) 2012-04-04
AU2009230801A1 (en) 2009-11-19
US20100105953A1 (en) 2010-04-29
CA2485346A1 (en) 2003-12-24
JP2005533789A (ja) 2005-11-10
US20140206865A1 (en) 2014-07-24
ES2425013T3 (es) 2013-10-10

Similar Documents

Publication Publication Date Title
JP4718172B2 (ja) ヒトａｄａｍ−１０インヒビター
JP4427328B2 (ja) ヒト−ａｄａｍ−１０インヒビター
US20120270884A1 (en) Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors
CZ292942B6 (cs) Derivát (N-hydroxykarbamoyl)-1-(4-fenoxy)benzensulfonylu
NO314079B1 (no) Visse cykliske tiosubstituerte acylaminosyreamidderivater
EP0421861A1 (fr) Dérivés d'hydroxy-2 thiophène et furanne condensés avec un cycle azoté, leur procédé de préparation et leur application en thérapeutique
HUP0200213A2 (en) Alkynyl containing hydroxamic acid compounds as tace inhibitors, process for their preparation and pharmaceutical compositions containing them
EP1217002B1 (fr) 2-(4-pyridinyl)-benzofurans comme inhibiteurs de métalloprotéases
JP2003524617A (ja) アセチレンアリールスルホンアミドおよびホスフィン酸アミドヒドロキサム酸ｔａｃｅ阻害剤
EP1065209B1 (fr) Nouveaux inhibiteurs de métalloprotéases, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
HUP0200605A2 (hu) Hidroxámsavszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
US8426415B2 (en) Human ADAM-10 inhibitors
JP2002535399A (ja) ヘテロアリールアセチレンスルホンアミドおよびホスフィン酸アミドヒドロキサム酸ｔａｃｅ阻害剤
FR2819253A1 (fr) Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091222

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100318

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101222

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110331

R150 Certificate of patent or registration of utility model

Ref document number: 4718172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees